ABSTRACT

Introduction: Lisocabtagene Maraleucel (Liso-cel) is a second-generation Chimeric Antigen Receptor T-cell (CAR-T) therapy product targeting CD19. It is currently being evaluated for B-cell lymphomas with pivotal trials conducted in Aggressive B-cell Lymphomas

Areas covered: To prepare this article reviewing preclinical and clinical data studying Liso-cel, we performed a Pubmed search using the terms ‘JCAR017’ and ‘Lisocabtagene maraleucel’. Pre-clinical work done with Liso-cel demonstrate the synergistic activity of CD4 + T-cells and CD8+ central memory T-cells (TCM) at a predefined ratio of 1:1. The trial, TRANSCEND NHL001 in aggressive B-cell lymphoma, confirms robust antitumor activity while demonstrating manageable toxicity profile.

Expert Opinion: There are inherent differences amongst the three CD19 directed CAR-T products. This could explain the differences in efficacy and safety profiles of the products. In the absence of randomized data, it would be scientifically unsound to prioritize one product over another. Nevertheless, when aiming to balance efficacy and safety, current prospective data indicate that Liso-cel is well positioned with impressive response rates

摘要

简介： Lisocabtagene Maraleucel（Liso-cel）是第二代靶向CD19的嵌合抗原受体T细胞（CAR-T）治疗产品。目前正在评估 B 细胞淋巴瘤，并在侵袭性 B 细胞淋巴瘤中进行了关键试验

涵盖的领域：为了准备这篇文章，回顾研究 Liso-cel 的临床前和临床数据，我们使用术语“JCAR017”和“Lisocabtagene maraleucel”进行了 Pubmed 搜索。使用 Liso-cel 完成的临床前工作证明了 CD4 + T 细胞和 CD8 + 中央记忆 T 细胞 (TCM) 以 1:1 的预定义比例具有协同活性。TRANSCEND NHL001在侵袭性 B 细胞淋巴瘤中的试验证实了强大的抗肿瘤活性，同时展示了可控的毒性特征。

专家观点：三种CD19导向的CAR-T产品存在内在差异。这可以解释产品功效和安全性的差异。在没有随机数据的情况下，将一种产品优先于另一种产品在科学上是不合理的。然而，当旨在平衡疗效和安全性时，当前的前瞻性数据表明 Liso-cel 处于有利地位，具有令人印象深刻的反应率